These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 19723877)
1. Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line. Karanikolas BD; Figueiredo ML; Wu L Mol Cancer Res; 2009 Sep; 7(9):1456-65. PubMed ID: 19723877 [TBL] [Abstract][Full Text] [Related]
2. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Berezovska OP; Glinskii AB; Yang Z; Li XM; Hoffman RM; Glinsky GV Cell Cycle; 2006 Aug; 5(16):1886-901. PubMed ID: 16963837 [TBL] [Abstract][Full Text] [Related]
3. Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines. Karanikolas BD; Figueiredo ML; Wu L Prostate; 2010 May; 70(6):675-88. PubMed ID: 20087897 [TBL] [Abstract][Full Text] [Related]
4. Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer. Hoffmann MJ; Engers R; Florl AR; Otte AP; Muller M; Schulz WA Cancer Biol Ther; 2007 Sep; 6(9):1403-12. PubMed ID: 18637271 [TBL] [Abstract][Full Text] [Related]
5. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Cao Q; Yu J; Dhanasekaran SM; Kim JH; Mani RS; Tomlins SA; Mehra R; Laxman B; Cao X; Yu J; Kleer CG; Varambally S; Chinnaiyan AM Oncogene; 2008 Dec; 27(58):7274-84. PubMed ID: 18806826 [TBL] [Abstract][Full Text] [Related]
6. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. Saramäki OR; Tammela TL; Martikainen PM; Vessella RL; Visakorpi T Genes Chromosomes Cancer; 2006 Jul; 45(7):639-45. PubMed ID: 16575874 [TBL] [Abstract][Full Text] [Related]
7. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis. Cheng AS; Lau SS; Chen Y; Kondo Y; Li MS; Feng H; Ching AK; Cheung KF; Wong HK; Tong JH; Jin H; Choy KW; Yu J; To KF; Wong N; Huang TH; Sung JJ Cancer Res; 2011 Jun; 71(11):4028-39. PubMed ID: 21512140 [TBL] [Abstract][Full Text] [Related]
8. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells. Li H; Cai Q; Godwin AK; Zhang R Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743 [TBL] [Abstract][Full Text] [Related]
9. The effect of prostate tissue inflammation in benign prostatic hyperplasia on enhancer of zeste homolog 2 ribonucleic acid expression. Al-Maghrebi M; Kehinde EO; Al-Mulla F; Anim JT Ann Saudi Med; 2012; 32(3):262-8. PubMed ID: 22588437 [TBL] [Abstract][Full Text] [Related]
10. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance. Kikuchi J; Kinoshita I; Shimizu Y; Kikuchi E; Konishi J; Oizumi S; Kaga K; Matsuno Y; Nishimura M; Dosaka-Akita H Cancer; 2010 Jun; 116(12):3015-24. PubMed ID: 20564407 [TBL] [Abstract][Full Text] [Related]
11. EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression. Fan T; Jiang S; Chung N; Alikhan A; Ni C; Lee CC; Hornyak TJ Mol Cancer Res; 2011 Apr; 9(4):418-29. PubMed ID: 21383005 [TBL] [Abstract][Full Text] [Related]
12. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. Chen H; Tu SW; Hsieh JT J Biol Chem; 2005 Jun; 280(23):22437-44. PubMed ID: 15817459 [TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412 [TBL] [Abstract][Full Text] [Related]
14. Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma. Vo BT; Li C; Morgan MA; Theurillat I; Finkelstein D; Wright S; Hyle J; Smith SMC; Fan Y; Wang YD; Wu G; Orr BA; Northcott PA; Shilatifard A; Sherr CJ; Roussel MF Cell Rep; 2017 Mar; 18(12):2907-2917. PubMed ID: 28329683 [TBL] [Abstract][Full Text] [Related]
16. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Kleer CG; Cao Q; Varambally S; Shen R; Ota I; Tomlins SA; Ghosh D; Sewalt RG; Otte AP; Hayes DF; Sabel MS; Livant D; Weiss SJ; Rubin MA; Chinnaiyan AM Proc Natl Acad Sci U S A; 2003 Sep; 100(20):11606-11. PubMed ID: 14500907 [TBL] [Abstract][Full Text] [Related]
17. The role of EZH2 in the regulation of the activity of matrix metalloproteinases in prostate cancer cells. Shin YJ; Kim JH PLoS One; 2012; 7(1):e30393. PubMed ID: 22272343 [TBL] [Abstract][Full Text] [Related]
18. The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma. Sasaki M; Ikeda H; Itatsu K; Yamaguchi J; Sawada S; Minato H; Ohta T; Nakanuma Y Lab Invest; 2008 Aug; 88(8):873-82. PubMed ID: 18591938 [TBL] [Abstract][Full Text] [Related]
19. Histone methyltransferase EZH2 induces Akt-dependent genomic instability and BRCA1 inhibition in breast cancer. Gonzalez ME; DuPrie ML; Krueger H; Merajver SD; Ventura AC; Toy KA; Kleer CG Cancer Res; 2011 Mar; 71(6):2360-70. PubMed ID: 21406404 [TBL] [Abstract][Full Text] [Related]
20. Enhancer of zeste homolog 2 overexpression has a role in the development of anaplastic thyroid carcinomas. Borbone E; Troncone G; Ferraro A; Jasencakova Z; Stojic L; Esposito F; Hornig N; Fusco A; Orlando V J Clin Endocrinol Metab; 2011 Apr; 96(4):1029-38. PubMed ID: 21289264 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]